| |
| | Valaciclovir: key clinical papers |
 | | The bioavailability of aciclovir after valaciclovir, characterised from studies in healthy adult volunteers, is similar in a wide range of patient populations, including the elderly, those with advanced HIV disease, patients with impaired liver or renal function, or undergoing bone marrow transplantation. |
 | | In a series of controlled, randomised trials of valaciclovir, aciclovir and placebo for the acute treatment of genital HSV infections in approximately 3000 patients, twice daily valaciclovir was proven as effective as the standard 5 times daily aciclovir regimen in resolving the clinical signs and symptoms of lesional disease. |
 | | The aciclovir safety heritage and pharmacokinetic rationale for the development of valaciclovir have been realised through the clinical research programmes in the zoster and HSV indications. |
| www.herpesweb.net /profess/effective/hmang13.htm (1998 words) |
|